Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480341 | 0.80 | PPARA (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL6474766 | 0.79 | SENP1 (0.48) | POLBSMN1; SMN2KMT2ANR3C2MGLL | |
| SCHEMBL6476491 | 0.76 | SMN1; SMN2 (0.44) | PDE4DCNR1SMPD1SMN1; SMN2LMNA | |
| SCHEMBL6474487 | 0.73 | PPARA (0.39) | ALDH1A1 | |
| SCHEMBL6474331 | 0.72 | ERAP1 (0.38) | POLBSMN1; SMN2LMNAMGLLALDH1A1 | |
| SCHEMBL4091879 | 0.71 | CNR1 (0.71) | CNR1MGLL | |
| SCHEMBL3791269 | 0.69 | PDE4D (0.86) | PDE4DPOLBHTTSMN1; SMN2LMNA | |
| SCHEMBL3417457 | 0.67 | ENPP2 (0.49) | CNR1MGLL | |
| SCHEMBL8883356 | 0.66 | SIGMAR1 (0.62) | SMN1; SMN2NR3C2ALDH1A1 | |
| SCHEMBL791693 | 0.64 | NPC1 (0.50) | PDE4DCNR1C5AR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930131-B2 | Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) | WYETH (US) | 2005-08-16 | — | — | US | disclosed |
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | GPR119, INSR, SLC5A1 | PDE4D 1407/4885POLB 3924/4885CNR1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.